Amgen reported top‑line results from the VESALIUS‑CV trial showing its PCSK9 inhibitor Repatha reduced first‑time major cardiovascular events by about 25% when added to standard therapy in high‑risk patients without prior heart attack or stroke. The data, published in the New England Journal of Medicine and presented at the American Heart Association meeting, showed a 36% reduction in first heart attacks in the studied population. VESALIUS‑CV also met secondary endpoints, including reductions in coronary death, heart attack and stroke, and fewer revascularization procedures. The trial enrolled patients already on statins or other lipid‑lowering drugs; investigators highlighted clinically meaningful prevention in a primary‑prevention‑style cohort. Regulators and payers will weigh these results against existing therapies as Amgen positions Repatha for expanded indications. The findings sharpen the competitive landscape for lipid‑lowering strategies and may influence guideline committees; Repatha’s reduced event rates and lower procedure needs will be evaluated for cost‑effectiveness and real‑world impact.